Daptomycin vs Gramicidin
Cyclic lipodepsipeptide antibiotic containing 13 amino acids and a decanoyl lipid tail from Streptomyces roseosporus — FDA-approved as Cubicin for complicated skin infections (2003) and S. aureus bacteremia including right-sided endocarditis (2006), operating through calcium-dependent phosphatidylglycerol-specific membrane depolarization with rapid bactericidal activity against MRSA, VRE, and other multidrug-resistant Gram-positive pathogens
Historic 15-amino-acid linear pentadecapeptide antibiotic with alternating D- and L-amino acids — the first commercially produced antibiotic discovered by René Dubos in 1939, forming monovalent cation-selective transmembrane channels in bacterial membranes, FDA-approved as a topical/ophthalmic antimicrobial component of Neosporin and related preparations
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Daptomycin
6–6 mg/kg
Gramicidin
0.025–0.025 mg/mL
Frequency
Daptomycin
Once daily
Gramicidin
Multiple times daily
Administration
Daptomycin
Intravenous infusion over 30 minutes (on the FDA label; 60 minutes for younger children)
Gramicidin
Topical application (primary clinical route)
Cycle length
Daptomycin
7-14 days for skin infection, 2-6 weeks for bacteraemia
Gramicidin
8-12 weeks
Onset speed
Daptomycin
Rapid (hours to days)
Gramicidin
Rapid (hours to days)
Evidence level
Daptomycin
Strong human trials (Phase 3 or FDA approved)
Gramicidin
Strong human trials (Phase 3 or FDA approved)
Benefit ratings
Fighting Drug-Resistant Infections
Bloodstream Infections
Skin Infection Treatment
Bacterial Infection Treatment
Eye Infection Care
Wound Protection
Compound specifications
Daptomycin
Molecular formula
C₇₂H₁₀₁N₁₇O₂₆
Molecular weight
1,620.69 Da
Half-life
Terminal half-life: 8-9 hours in healthy adults with normal renal function; supports once-daily dosing; post-antibiotic effect: 1-6 hours against S. aureus; renal dose adjustment: CrCl <30 mL/min — extend interval to every 48 hours
Bioavailability
IV: 100% (direct administration); not orally bioavailable (degraded in GI tract); inactivated in lungs by pulmonary surfactant
CAS number
103060-53-3
Gramicidin
Molecular formula
C₉₉H₁₄₀N₂₀O₁₇ (gramicidin A)
Molecular weight
1,882.3 Da (gramicidin A); Gramicidin D mixture: ~1,880-1,900 Da average
Half-life
Local tissue persistence: hours to days at topical application sites (protease-resistant D-amino acid structure); systemic half-life: not applicable (hemolytic — never administered systemically); single channel lifetime: ~1 second (open/close kinetics in electrophysiology)
Bioavailability
Topical: local tissue concentrations at application site; systemic absorption negligible through intact skin and eye; oral bioavailability: not applicable (not used orally for systemic effect; would cause GI hemolysis); intrinsically resistant to proteases due to D-amino acid content
CAS number
11029-61-1 (gramicidin A); 1405-97-6 (gramicidin D mixture)
Dosing compared
Daptomycin
Intravenous
4 mg/kg
Once every 24 hours · 7–14 days
The FDA-approved adult dose for complicated skin and skin-structure infections: 4 mg/kg every 24 hours for 7 to 14 days, intravenously in 0.9% sodium chloride, either as a 2-minute injection or a 30-minute infusion [6]. Below a creatinine clearance of 30 mL/min — including haemodialysis and CAPD — the same dose moves to every 48 hours, given after dialysis on dialysis days [6].
6 mg/kg
Once every 24 hours · 2–6 weeks
The FDA-approved adult dose for Staphylococcus aureus bloodstream infection, including right-sided infective endocarditis: 6 mg/kg every 24 hours for 2 to 6 weeks, every 48 hours below a creatinine clearance of 30 mL/min [6]. It is NOT approved for left-sided infective endocarditis, and NOT for pneumonia — pulmonary surfactant inactivates the drug directly [1][6].
8–12 mg/kg
Once every 24 hours · 2–6 weeks
Off-label in adults, and on-label in small children — the same numbers mean different things depending on who is being dosed. For children the label sets 12 mg/kg every 24 hours for ages 1 to 6 with S. aureus bacteraemia, 9 mg/kg for 7 to 11 and 7 mg/kg for 12 to 17, because clearance is faster [6]. In adults, above 6 mg/kg is off-label. The meta-analysis is not equivocal about the trade-off: in complicated bacteraemia and infective endocarditis, standard dosing succeeded significantly LESS often than high dosing (odds ratio 0.48, 95% CI 0.30-0.76 and 0.50, 0.30-0.82), and less often still against 8 mg/kg or more (0.38, 0.21-0.69 and 0.30, 0.15-0.60) — while the incidence of raised CPK was significantly lower on standard dosing [5]. In osteomyelitis and prosthetic infection, standard dosing did not do worse [5]. The label requires weekly CPK monitoring, more often in renal impairment or alongside a statin [6].
Gramicidin
Topical
Gramicidin 0.025 mg/mL (in neomycin/polymyxin B/gramicidin ophthalmic solution); instill 1-2 drops
Every 4 hours (up to 2 drops every hour for severe infection) · 7-10 days
FDA-labeled combination ophthalmic solution for superficial external eye infections; gramicidin is the gram-positive component. Not for injection into the eye [6].
Best suited for
Daptomycin
Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
Daptomycin is particularly well-suited for individuals focused on treatment of mrsa bacteremia and right-sided infective endocarditis (fda-approved indication at 6 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
Daptomycin is particularly well-suited for individuals focused on complicated skin and skin structure infections including surgical site infections and diabetic foot infections (fda-approved at 4 mg/kg). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
Daptomycin is particularly well-suited for individuals focused on vre bloodstream infections and endocarditis when ampicillin-based therapy is not feasible. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Daptomycin is particularly well-suited for individuals focused on outpatient parenteral antibiotic therapy (opat) for gram-positive infections requiring iv treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Gramicidin
Topical treatment of bacterial conjunctivitis and external eye infections (FDA-approved)
Gramicidin is particularly well-suited for individuals focused on topical treatment of bacterial conjunctivitis and external eye infections (fda-approved). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (OTC topical preparations)
Gramicidin is particularly well-suited for individuals focused on prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (otc topical preparations). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Research into ion channel biophysics, single-channel electrophysiology, and membrane transport mechanisms
Gramicidin is particularly well-suited for individuals focused on research into ion channel biophysics, single-channel electrophysiology, and membrane transport mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Combination topical antimicrobial therapy providing Gram-positive coverage alongside polymyxin B for Gram-negatives
Gramicidin is particularly well-suited for individuals focused on combination topical antimicrobial therapy providing gram-positive coverage alongside polymyxin b for gram-negatives. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Side effects
Daptomycin
Common
- CPK elevation
- GI effects (nausea, diarrhea, vomiting)
- Headache and insomnia
- Injection site reactions
Uncommon
- Eosinophilic pneumonia
Serious
- Rhabdomyolysis
Gramicidin
Common
- Ophthalmic stinging/burning
- Local skin irritation
- Temporary blurred vision
- Contact sensitization
Uncommon
- Superinfection
Serious
- Hemolytic toxicity with systemic absorption
Safety & evidence
Daptomycin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for complicated skin and skin-structure infections (adults and children 1-17) and for Staphylococcus aureus bloodstream infection (adults including right-sided endocarditis, and children 1-17). NOT indicated for pneumonia, NOT for left-sided endocarditis, NOT recommended under 1 year of age.
Safety overview
The label's limitations of use are the sharpest safety facts here, because they describe failure rather than toxicity: daptomycin is not indicated for pneumonia, because pulmonary surfactant inactivates it directly [1][6], and not for left-sided infective endocarditis due to S. aureus [6]. On toxicity, myopathy is defined on the label as muscle aching or weakness with CPK above ten times the upper limit of normal, and rhabdomyolysis with or without acute renal failure has been reported; CPK is to be monitored weekly, and more often in renal impairment or alongside a statin [6]. The largest statin comparison found myalgias in 3 of 49 (6.1%) on the combination against 5 of 171 (2.9%) on daptomycin alone (p=0.38), and CPK above 1,000 U/L in 5 of 49 (10.2%) against 9 of 171 (5.3%) (p=0.32) — numerically worse, not statistically so, and reversible on stopping [2]. The label also warns of anaphylaxis, eosinophilic pneumonia, DRESS, tubulointerstitial nephritis, peripheral neuropathy, Clostridioides difficile diarrhoea, and reduced efficacy in adults with moderate baseline renal impairment [6]. Higher doses cost more muscle enzyme elevation: CPK rises were significantly more frequent above 6 mg/kg than at standard dose [5].
Contraindications
- Known hypersensitivity to daptomycin — the FDA label's only stated contraindication
- Pneumonia or any lower respiratory tract infection — pulmonary surfactant inactivates daptomycin directly, the first described case of organ-specific inhibition of an antibiotic, and the label states it is not indicated for pneumonia
- Left-sided infective endocarditis due to S. aureus — a stated limitation of use on the label
- Children under 1 year — the label does not recommend it, because of muscular, neuromuscular and nervous system effects seen in neonatal dogs
- Concurrent statins are not an absolute contraindication but need more frequent CPK monitoring; the largest comparison found numerically but not statistically higher musculoskeletal toxicity
Gramicidin
Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Gramicidin is a cyclic peptide antibiotic derived from Bacillus brevis with a 70+ year track record of topical safety. It functions as a pore-former in bacterial membranes and shows minimal systemic absorption when applied to intact skin or mucous membranes, making it extremely low-toxicity for localized use. The primary safety concern is sensitization reactions in 1-5% of users with prolonged exposure, not organ toxicity. Gramicidin is FDA-approved for topical antibacterial applications and generally well-tolerated across age groups.
Contraindications
- Known hypersensitivity to gramicidin or any component of topical/ophthalmic formulations
- Systemic administration by any route — gramicidin is hemolytic and toxic to red blood cells; strictly topical/ophthalmic use only
- Deep puncture wounds or severe burns requiring systemic antimicrobial coverage
- Prolonged use on large open wounds — even topical gramicidin may cause hemolysis if absorbed systemically through extensive denuded skin
Which is right for you?
Choose Daptomycin if...
- Treatment of MRSA bacteremia and right-sided infective endocarditis (FDA-approved indication at 6 mg/kg)
- Complicated skin and skin structure infections including surgical site infections and diabetic foot infections (FDA-approved at 4 mg/kg)
- VRE bloodstream infections and endocarditis when ampicillin-based therapy is not feasible
- Outpatient parenteral antibiotic therapy (OPAT) for Gram-positive infections requiring IV treatment
Choose Gramicidin if...
- Topical treatment of bacterial conjunctivitis and external eye infections (FDA-approved)
- Prophylaxis and treatment of superficial skin infections, minor cuts, scrapes, and burns (OTC topical preparations)
- Research into ion channel biophysics, single-channel electrophysiology, and membrane transport mechanisms
- Combination topical antimicrobial therapy providing Gram-positive coverage alongside polymyxin B for Gram-negatives